Open Access Research Article

HDAC Inhibitors as Anticancer Therapeutics

Sidra Shafique*

Department of Reproduction and Developmental Sciences DBMS, Queen’s University Kingston, Canada

Corresponding Author

Received Date:September 13, 2018;  Published Date: October 04, 2018

Abstract

Underlying mechanisms of carcinogenic aberrations in genome stems from genetic mutations and epigenetic modulations followed by a cascade of mechanistic events in signaling pathways. Acetylation status have been identified as one of the key markers of cancerous cells along with the over expression of Histone deacetylases (HDACs). In this context, HDACs are the focus of cancer research both from the cause and the treatment perspectives. HDAC inhibitors are one of the time-tested therapeutics and have recently been used as an effective adjuvant with the combination therapeutic regimens of cancers such as breast cancer. Here, we discuss the HDAC inhibitors as cancer treatment option in context with carcinogenic role of epigenetic modifications.

Citation
Signup for Newsletter
Scroll to Top